This autumn Britain becomes the first country to launch a new vaccine against
group C meningitis, which is expected to dramatically cut the death toll from
the disease. Existing vaccines only protect for up to two years, and do not work
in infants under two. The new vaccine should overcome these problems, and will
initially be targeted at young children and teenagers. However, 60 per cent of
meningitis cases in Britain are of the slightly less deadly group B. Vaccines
against this bacteria are being tested
(Technology, 24 May 1997, p 20), but are
unlikely to be available for several years.
More from New Scientist
Explore the latest news, articles and features
Popular articles
Trending New Scientist articles
1
We've found a mysterious substance on Titan and Pluto
2
A quantum state that lasts forever may finally be within our grasp
3
Remarkable fossils rewrite the story of how animals conquered the land
4
Unpicking the genetics of fibromyalgia sheds new light on its causes
5
What’s the secret to living well beyond the average life expectancy?
6
Technology is changing our perspective on nature – at every scale
7
Can prebiotics, probiotics or postbiotics help your ageing microbiome?
8
How I used psychology to come back from the worst year of my life
9
The secrets to keeping your brain sharp in old age
10
Has the answer to life's origins been hiding in our cells all along?
